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Sleep disordered breathing in ESRD: Acute beneficial effects of treat-
ment with nasal continuous positive airway pressure. Complaints about
sleep and daytime alertness are common in ESRD patients. Eight
consecutive ESRD patients with a sleep complaint were studied with
all-night polysomnography. All were found to have significant sleep
apnea with a mean apnealhypopnea index (AHI) of 64 41.6 episodes
per hour of sleep (range 7.5 to 140/hr of sleep), The majority of apneas
were of the central or mixed variety causing severe fragmentation of
sleep and frequent awakenings. Treatment was attempted with nasal
continuous positive airway pressure (NCPAP). NCPAP was highly
successful in six of the eight patients, reducing the mean AHI to normal
or near normal levels (6.0 3.8/hrof sleep, P < 0,02vs. baseline). The
quality of sleep was significantly improved with statistically significant
decreases in light stage I sleep, and nocturnal oxygenation improved
with statistically significant increases in low Sa02 values. Five of six
responders reported that they awoke feeling more alert and fewer times
from sleep. The etiology of sleep apnea in ESRD is unknown although
the frequent central apneas suggest a dysfunction of central respiratory
control resulting from the effects of renal failure, Sleep-related com-
plaints in patients with ESRD are likely to result from sleep apnea, a
sleep disorder that can be diagnosed with polysomnography and treated
with NCPAP.
End-stage renal disease (ESRD) has long been associated
with reports of disturbed sleep [1, 2]. Recent surveys have
found that 41 to 63% of hemodialysis patients complain of
significant sleep problems [3, 4]. Objective polysomnographic
studies relate these sleep complaints primarily to sleep apnea
and periodic leg movements in sleep 13, 5—7]. The incidence of
sleep apnea in ESRD appears to be higher than that found in the
general population where sleep apnea is reported to occur at a
rate of 0.9 to 7.8% [8, 9]. A recent study found that 73% of
hemodialysis patients with a sleep complaint had severe sleep
apnea [5]. Other studies have demonstrated sleep apnea in 53%
and 75% of ESRD patients with a sleep complaint [3, 6]. These
studies suggest an incidence of sleep apnea in the ESRD
population of 21 to 47%, considerably in excess of the estimates
for the general population.
The overwhelming majority of apneas in the general popula-
tion are of the obstructive type, resulting from collapse of the
upper airway, usually at the level of the oropharynx [10, 11].
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However, in the ESRD population, central apneas resulting
from a pause or reduction in central respiratory drive are more
frequent, accounting for 48.6% of all sleep disordered breathing
during non-rapid eye movement sleep (NREM) sleep and 20.4%
of sleep disordered breathing in rapid eye movement sleep
(REM) sleep [5]. The pathophysiology of sleep apnea in the
ESRD population is unknown. The frequent occurrence of
central apneas suggests dysfunction in the respiratory control
centers of the brain. Explanations include possible direct effects
of uremia on the central nervous system and/or respiratory
musculature, low pCO2 resulting from chronic metabolic acido-
sis and ventilatory control instability [6, 12—15].
A variety of therapeutic approaches for central apnea have
been proposed. These include mechanical ventilation, supple-
mental oxygen, medications such as acetazolamide and theoph-
ylline, and nasal continuous positive airway pressure (NCPAP)
[17—22]. There are no published reports of attempts to treat the
sleep apnea of ESRD with these methods. Conventional hemo-
dialysis has not been shown to be an effective treatment for
sleep apnea in ESRD, although Fein and colleagues have
reported almost complete elimination of sleep apnea with
dialysis in a single, previously untreated, severely uremic,
elderly patient 16, 16].
NCPAP is the current state of the art treatment for obstruc-
tive sleep apnea [23]. It consists of the administration of
positive air pressure via a nasal mask in order to increase the
positive air pressure in the upper airway and prevent collapse.
Although NCPAP is the primary treatment for obstructive sleep
apnea, it has also been reported to be effective in the treatment
of some patients with central sleep apnea [22]. The success of
NCPAP as a treatment for central sleep apnea may indicate that
some level of obstruction is present. Alternately, the positive
pressure has been hypothesized to stimulate upper airway
reflexes.
This paper describes the results of treating sleep apnea in a
group of ESRD patients with NCPAP.
Methods
Subjects were eight consecutive renal failure patients (6 men
and 2 women), mean age of 52.4 15.5 years, referred for
complaints of excessive daytime sleepiness, disrupted noctur-
nal sleep or sleep onset insomnia (Table 1). All patients had
been diagnosed with ESRD. Six patients received hemodialy-
sis, one received CAPD and one had not yet begun dialysis. A
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Table 1. Patient demographics and blood work
Patient
Age
yrs Sex BMI rHuEPO MB
HCT
%
BUN
mg%
HCO3
meqiliter
Glu
mg%
DD
yrs
1 36 M 31.9 Yes CA 33 53 23 128 3.0
2 53 M 24.5 No CU 22 67 26 126 7.0
3 41 F 36.9 Yes PM 32 72 21 254 3.5
4 37 M 25.2 Yes CU 23 97 21 143 1,3
5 71 F 27.9 Yes PM 33 55 20 148 1.5
6 69 M 27.8 No PD 34 62 31 97 0.9
7 42 M 23.9 No CU 32 57 20 82 2.5
8 70 M 28.7 No — 32 61 29 143 —
Abbreviations are: BMI, body mass index; rHuEPO, recombinant human erythropoietin; MB, type of dialysis membrane; CA, cellulose acetate;
CU, cupraphane, PM, polymethylmethacralate; PD, peritoneal dialysis; HCO3 = bicarbonate level; BUN, blood urea nitrogen; HCT, hematocrit;
DD, duration of dialysis in years.
body mass index (B MI) was computed for each patient (Table I)
[24]. Four of the patients were receiving recombinant human
erythropoietin (rHuEPO) during both phases of this study.
All patients underwent a standard polysomnographic evalu-
ation including simultaneous measurement of ERG (C3 or C4),
electro-oculogram, electromyogram (mentalis muscle), ECG,
airflow, respiratory effort (abdominal and chest movement),
oxygen saturation, body position, breathing sounds, and right
and left anterior tibialis electromyogram. All patients had
routine blood work including hematocrit, BUN, HCO3 and
glucose.
All patients were found to have an apnealhypopnea index of
 5.0/hr of sleep and returned for a treatment trial of NCPAP.
All physiologic parameters mentioned above were again moni-
tored. The NCPAP treatment consisted of appropriate fitting
and placement of the NCPAP mask prior to sleep and the
application of air pressure through the nares using the nasal
mask during sleep. Pressure was generated with a Respironics
Sleep Eazy Plus NCPAP machine or BiPAP machine in CPAP
mode. Air pressure was started at 5 cm H20 and slowly
increased until maximum reduction of apneas, hypopneas and
snoring was achieved.
Central sleep apneas were defined by the absence of airflow
and respiratory effort lasting for at least 10 seconds. Hypopneas
were defined by at least a 20% reduction in airflow and/or effort
lasting for at least 10 seconds. This was required to be associ-
ated with 2% or greater 02 desaturation and/or clear electro-
graphic changes associated with arousal or awakening from
sleep. Obstructive apneas were defined by the complete ab-
sence of airflow with continued respiratory effort for at least 10
seconds with associated 02 desaturation  2% and/or clear
electrographic signs of arousal or awakening from sleep. Mixed
apneas were defined by the initial presence of central apnea
followed by return of respiratory effort without airflow. An
apnealhypopnea index (AHI) was computed (apneas + hypop-
neas/total sleep time in hours).
Respiratory airflow was measured using thermistors at the
right and left nares, and at the mouth. Thermistors measure
changes in temperature of air entering and exiting the nares and
mouth, and are standard equipment in many sleep laboratories.
However, thermistors are indirect and uncalibrated measures of
airflow. In the absence of invasive and more accurate measure-
ment techniques such as esophageal balloons, it is possible that
some airflow persisted and was undetected due to the lower
sensitivity of the thermistors. Thus, although the changes used
to define complete absence of airflow certainly represent very
large relative reductions in airflow, the complete absence of
airflow cannot be absolutely confirmed using thermistors.
During administration of NCPAP an AHI was computed for
each level of CPAP pressure administration. As NCPAP is
titrated against the number and frequency of apneas and hy-
popneas that appear in the sleep recording, the duration that a
particular level of NCPAP was administered varied consider-
ably. Early levels of NCPAP treatment may reduce the AHI
from a severe level to a moderate level. As a moderate level is
not considered adequate treatment, the NCPAP pressure would
then be increased again until maximum reduction in the AHI
was achieved. Data reported in the results section (Table 2)
represent the AHI determined for the optimal NCPAP pressure.
Periodic leg movements in sleep (PLMS) were defined as
increased EMG activity at the right or left anterior tibialis
muscle lasting 0.5 to 4.0 seconds and occurring in a series of at
least four movements with an intermovement interval of 4 to 90
seconds. The EEG during and immediately following the ap-
pearance of PLMS was also inspected to determine if the PLMS
resulted in arousal from sleep. PLMS and arousing PLMS
(APLMS) indexes were computed by then dividing the number
of PLMS and APLMS by the total sleep time in hours.
All patients receiving hemodialysis underwent both diagnos-
tic testing and NCPAP treatment trials on the nights prior to
hemodialysis.
All data were visually analyzed by one of us (MRP) or one of
our technical staff using standard techniques utilizing a comput-
er-based semi-automatic sleep scoring system (SASSSY, Tele-
factor Corporation, Conshohocken, Pennsylvania, USA) [25,
26]. Non-REM stages 3 and 4 were combined to form slow wave
sleep (SWS). The standard conventions of sleep staging re-
quires analysis of sleep in 20 or 30 second epochs. The
definition of sleep stages 3 and 4 are based on the relative
percentage of delta waves (EEG in the 0.5 to 3.0 hz range) in
each epoch. The definitions of sleep stage 3 as 20 to 50% delta
waves in the given epoch and sleep stage 4 as more than 50%
delta waves in given epoch are not based on empirical data. As
a result the two sleep stages are often combined and presented
as SWS.
All patients completing both diagnostic polysomnography
and NCPAP trial were entered into the statistical analysis. Pre-
and post-comparisons were made with t-tests for correlated
samples (Statgraphics). Additionally, the relationship of BUN,
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Table 2. Sleep and respiratory data
Patient
# AHI
Mean
Sa02
Low
Sa02 CPAP
AHI
CPAP
mean
Sa02
CPAP
low
Sa02
Optimal
CPAP
pressure
cmH2O% %
1 51.8 96 89 3.0 98 97 5.0
2 51.6 93 76 3.6 95 92 10.0
3 7.5 93 89 1.6 93 89 5.0
4 51.5 97 75 10.6 91 77 12.5
5 40.5 93 83 a
6 110.0 94 84 — — a
7 140.3 92 80 7.4 96 91 7.5
8 62.2 93 68 10.0 98 94 5.0
Mean 64,4b 939C 805d 6.0 95,2 90.0
SD 41.6 1.7 7.3 3.8 2.9 6.9
a Did not complete NCPAP trial
b 1-test for dependent samples vs. CPAP AHI, N = 6 (60.8 43.3 vs. 6.0 3.8, P < 0.02)
t-test for dependent samples vs. CPAP mean Sa02, N 6 (94.0 2.0 vs. 95.2 2.9, NS)d 1-test for dependent samples vs. CPAP Low Sa02, N = 6 (79.5 8.3 vs. 90.0 6.9, P < 0.04)
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Fig. 1. A 2.5 minute compressed portion of the polysomnogram of patient #5 showing repetitive short central sleep apneas and hypopneas
associated with sign 4/leant fragmentation of sleep and minimal 1 103% 02 desaturations. Only EEG and respiratory channels are shown. The letter
"C" indicates a central sleep apnea and the letter "H" indicates a hypopnea.
hematocrit, glucose and bicarbonate to AHI and sleep param-
eters were tested using regression analysis.
Results
All patients were found to have significant sleep apnea (Table
2) with a mean apnea/hypopnea index of 64.4 41 .6/hr of sleep.
In six of the eight patients sleep disordered breathing consisted
almost entirely of central apneas, central hypopneas (Fig. 1) or
mixed apneas (Fig. 2) with very long central components.
Snoring was occasionally heard in six of the eight patients at the
termination of central apneas and hypopneas, suggesting that
some obstruction was present. All apneas and hypopneas were
associated with 02 desaturations that typically ranged from ito
7% with occasional drops in Sa02 as low as 68%.
Six of the eight patients were found to have significant
numbers of periodic leg movements in sleep. A mean of 81.4
77.5 leg movements per study were noted for the whole group
with 39.8 44.3 resulting in arousal from sleep for 1 to 60
seconds each. The overall PLMS index was 14.7 15.9/hr of
sleep with an arousing PLMS index of 7.5 9.5/hr of sleep.
Body mass index (BMI) was negatively correlated with the
apnealhypopnea index (r = —0.63, P <0.09), but did not reach
statistical significance. This suggests that in this group of
patients the severity of sleep apnea increased as body mass
decreased. Three of the patients had BMI of less than 27,
considered to be within the normal range. Three of the patients
were slightly higher than 27, but still with Grade I or mild
obesity. The remaining two patients were moderately obese.
The quality of sleep was generally poor with light stage 1
sleep accounting for slightly more than 27% of total sleep time
(Table 3) instead of the expected 5 to 8%. Sleep efficiency was
poor with a mean of 75.8 33.6%.
NCPAP trials were completed in six of the eight patients. Of
the two patients who did not complete the NCPAP trial,
NCPAP was unsuccessful in one because of complaints of
discomfort with the NCPAP mask and apparatus as well as with
the sensation of positive air pressure. In a second patient, there
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Fig. 2. A 2.5 minute compressed portion of the polysomnogram of patient #2 showing repetitive, long mixed apneas with significant sleep
fragmentation and minimal 02 desaturations. The 'E" indicates a single out-of-phase movement of the chest and abdomen occurring without
concurrent airflow just before arousal from sleep. This is indicative of upper airway obstruction following a long period of central sleep apnea which
is characteristic of a mixed apnea.
Table 3. Sleep parameters
Baseline NCPAP P<
Total recording time 457.2 89.2 468.5 69.1 NS
Total sleep time 350.5 111.8 371 54.4 NS
Total wake time 107.2 50.8 97.5 52.0 NS
Sleep efficiency % 75.3 14.9 79.8 9.6 NS
Stage 1 mm 75.8 33.6 31.8 8.1 0.01
Stage 1 % 25.2 17.2 8.8 2.9 =0.06
Stage 2 mm 175.7 63.2 206.0 64.6 NS
Stage 2 % 49.6 6.8 55.0 14.5 NS
Slow wave sleep mins" 48.1 47.8 74.8 34.9 =0.21
Slow wave sleep % 12.1 11.1 20.0 10.6 =0.12
REM sleep mins 51.5 31.8 61.0 20.8 NS
REM sleep % 13.1 7.0 16.2 4.4 NS
a Slow wave sleep = Stage 3 + Stage 4
was an inability to breath nasally, permitting positive air
pressure to escape from the mouth. In the six patients who
completed the NCPAP treatment, AHI was significantly re-
duced (Table 2). NCPAP was highly successful in three patients
reducing the AHI to normal values of <5/hr of sleep. In three
other patients NCPAP was moderately successful, resulting in
an AHI between 7 to 11/hr of sleep, consistent with mild sleep
apnea. The mean baseline AHI for this group of six NCPAP
responders was 60.8 48.3 episodes per hour of sleep.
The quality of sleep was also improved during NCPAP
treatment, as shown in the significant reduction in light stage 1
sleep minutes (Table 3). Slow wave sleep (sleep stages 3 + 4)
showed a trend toward improvement, but did not attain statis-
tical significance.
NCPAP had a significant effect on low Sa02 values resulting
in an increase from a mean of 79.5 8.3% to 90.0 6.9% (P <
0.04). Mean 02 desaturations also increased from 94.0 2.0%
to 95.2 2.9%, but did not reach statistical significance.
During administration of NCPAP, the overall mean index of
periodic leg movements in sleep as well as the mean total
number of PLMS showed a non-significant trend for increasing
(14.7 15.9 vs. 28.2 29.5, NS and 81.4 77.5 vs. 162 172,
NS). The mean index of PLMS resulting in arousal as well as
the mean total number of PLMS resulting in arousal declined
(7.5 9.5 vs. 4.0 2.6, NS and 39.8 44.3 vs. 22.6 14.5,
NS).
On the morning after the NCPAP trial, two of the six patients
noted on the morning questionnaire that following the initial
NCPAP treatment their sleep was "much better than usual"
and three of six noted their sleep to have been "better than
usual". Only one patient felt he had slept "worse than usual".
Four of the six patients reported that they had awakened
"many fewer times than usual" from sleep. One noted he
awoke "fewer" times than usual and one noted he awoke
"more frequently". Four of the six patient reported that they
awoke "feeling more or much more alert than usual". Two of
the six patients reported that they awoke feeling less alert than
usual.
BUN, hematocrit, HCO3, glucose, rHuEPO and duration of
dialysis were not found to be significantly correlated with any of
the sleep disordered breathing parameters.
Discussion
All eight patients were found to have clinically significant
sleep apnea. The apnea/hypopnea index (AHI) placed seven of
eight patients in the range of severe sleep apnea (AHI >50/hr of
sleep) and one of eight in the mild-to-moderate range (AHI 5 to
20/hr of sleep). The majority of apneas were either central or
mixed with a very long central component, suggesting a dys-
function of central respiratory control. Apneas and hypopneas
resulted in significant disruption of sleep, accounting for the
patient's presenting complaints.
NCPAP proved to be a highly successful treatment, reducing
the AHI to normal or near normal levels. The success of
NCPAP in treating six of the eight patients suggests that airway
collapse or closure plays some role at least in initiating or
terminating apneas in these ESRD patients. Patients success-
fully treated with NCPAP still had occasional central sleep
apneas or hypopneas, but these rarely occurred repetitively.
NCPAP appeared to eliminate the repetitive, cyclical pattern of
apneas followed by deep breathing, followed by another central
apnea, etc. The degree of hyperpnea following apneas may be a
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function of the magnitude of respiratory drive necessary to
overcome upper airway occlusion at the end of apneas. By
preventing airway collapse the NCPAP may have eliminated
the deep breathing that results in hyperventilation and then
lowered respiratory drive, thus setting the stage for the next
central sleep apnea.
Alternatively, Issa and Sullivan's [22] explanation for suc-
cessful treatment of central apnea with NCPAP should be
considered. They reported that high levels of NCPAP (pres-
sures of 10 to 12.5 cm H20) were a successful treatment for
central sleep apnea and hypothesized that central sleep apnea
occurred following passive airway closure, which in turn
caused stimulation of the mucosal sensory receptors and reflex
apnea. High levels of NCPAP were postulated to prevent this
passive collapse and thus inhibit the apnea reflex.
Nocturnal oxygenation as measured by Sa02 was also im-
proved by NCPAP treatment with the low Sa02 values signifi-
cantly improved, so that in five of the six patients Sa02 values
did not decline lower than 89%. Additionally, NCPAP treat-
ment improved the objective quality of sleep along with the
patient's subjective impressions of sleep quality and daytime
alertness. The amount of stage 1 sleep was elevated during
baseline recording and significantly reduced during NCPAP.
This is one of many objective changes typical of successful
NCPAP treatment [27]. Stage 1 sleep is a light sleep usually
seen only during transitions from wakefulness to sleep. An
elevated amount or percentage of stage 1 is a good indication
that the patient is awakening frequently during sleep. REM
sleep and SWS also typically increase above expected normal
percentages during initial NCPAP treatment [28, 291. A trend in
this direction was noted. The failure of these values to reach
statistical significance was not unexpected. As noted in the
Methods section, the NCPAP recording night was a treatment
trial or titration night. Various pressures levels were applied
during sleep for varying periods of time in order to assess which
pressure level was most optimal in reducing the number of
apneas and hypopneas. During administration of suboptimal
pressures, apneas and hypopneas with associated fragmenta-
tion of sleep continued to appear, reducing the total quantity
and percentage of both SWS and REM sleep.
Significant controversy exists in the medical literature regard-
ing whether sleep fragmentation or hypoxemia during sleep is
primarily responsible for the daytime sleepiness and other
deficits in daytime functioning commonly found in patients with
obstructive sleep apnea [30—33]. Several studies suggest that
nocturnal hypoxemia is a major determinant of daytime sleep-
iness only in more severe sleep apnea associated with signifi-
cant °2 desaturations, while sleep fragmentation is the major
determinant of daytime sleepiness in milder sleep apnea. It is
important to note that the nocturnal hypoxemia of sleep apnea
in general and in the patients in this study consisted of repeti-
tive, but transient 02 desaturations, terminated at the end of
each apnea and usually returning to normal Sa02 values until
the next appearance of apnea or hypopnea. Thus, there was no
sustained, chronic hypoxemia of the sort that is found in
patients with COPD or hypoventilation. Most of the central
apneas were associated with clear, but minimal drops in Sa02
with occasional more significant drops. This is a common
finding in patients with idiopathic central apnea without hypo-
ventilation [34]. Bradley and colleagues reported that the major
determinants of 02 desaturations in obstructive sleep apnea are
waking Pa02, lung volumes and duration of apneas [34, 35]. All
of the patients in this group had normal baseline SaO, during
wakefulness and during periods of apnea and hypopnea-free
sleep. The literature on nocturnal hypoxemia and sleep frag-
mentation does not directly address the question of central
sleep apnea, but there is no reason to suppose that it would
differ in this regard from obstructive sleep apnea. Thus, as
nocturnal hypoxemia was relatively mild in this group of
patients, elimination of sleep fragmentation is most likely the
major determinant of improved daytime alertness.
The overall quality of sleep during NCPAP treatment may
have also been limited by the presence of a second sleep
disorder, Periodic Leg Movements in Sleep (PLMS). Six of the
eight ESRD patients also had PLMS during baseline recording
which contributed to the overall fragmentation of sleep (see
results section). As previously noted in patients with severe
obstructive sleep apnea, PLMS often increase in frequency
during NCPAP treatment and eventually become more disrup-
tive as normal sleep patterns return [36]. Four of the six patients
showed this pattern. It is hypothesized that PLMS increase in
frequency during NCPAP treatment because the frequent dis-
ruption of sleep by apneas and hypopneas during baseline
polysomnography interfered with their occurrence or concealed
their presence.
The success of NCPAP in treating the sleep apnea in six of
eight ESRD patients does not answer the question of why sleep
apnea appears to occur more frequently in this population. The
presence and severity of sleep apnea did not appear directly
related to the type of dialysis membranes used in this group.
Degree of azotemia, duration of time on dialysis, hematocrit,
rHuEPO and bicarbonate concentration did not appear to be
factors in predicting sleep apnea or response to NCPAP ther-
apy.
Complaints of insomnia in ESRD patients may also be
secondary to the effects of sleep apneas. Two of the patients in
this group presented with subjective complaints of severe sleep
onset insomnia with relatively minor additional complaints of
awakenings from sleep. Despite their subjective estimations of
long sleep onset latency, they were found to fall asleep rela-
tively quickly (< 10 minutes) and proceeded to have repetitive
apneas and hypopneas. When repetitive apneas and hypopneas
occur, the longest period of uninterrupted sleep is generally
equal to the longest apnea or hypopnea. Thus, the longest
period of uninterrupted sleep for these two patients did not
exceed 45 seconds. The frequent disruption of sleep may affect
the ability to perceive sleep as a state distinct from wakefulness
and lead to complaints of insomnia when significant sleep apnea
fragmented sleep is actually present.
All of the ESRD patients studied had complaints about their
sleep or daytime alertness that were found to be secondary to
well known sleep disorders, sleep apnea and periodic leg
movements in sleep. NCPAP was successfully administered to
six of the eight patients resulting in significant improvement in
the quality of sleep as well as improved subjective alertness.
Complaints of sleep disorders or impaired daytime alertness in
patients with ESRD should be aggressively investigated and
treated.
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